Frontmatter

Articles in the same Issue

1. Frontmatter
2. Editorial
3. Protein electrophoresis and serum free light chains in the diagnosis and monitoring of plasma cell disorders: laboratory testing and current controversies
4. Laboratory Testing as Recommended by the Guidelines and the International Myeloma Working Group
5. Laboratory testing requirements for diagnosis and follow-up of multiple myeloma and related plasma cell dyscrasias
6. Free light chain testing for the diagnosis, monitoring and prognostication of AL amyloidosis
7. Laboratory testing in monoclonal gammopathy of renal significance (MGRS)
8. The impact of renal function on the clinical performance of FLC measurement in AL amyloidosis
9. Serum and Urine Protein Electrophoresis and Immunofixation Testing
10. Challenges of measuring monoclonal proteins in serum
11. Screening immunofixation should replace protein electrophoresis as the initial investigation of monoclonal gammopathy: Point
12. Should routine laboratories stop doing screening serum protein electrophoresis and replace it with screening immune-fixation electrophoresis? No quick fixes: Counterpoint
13. Moving towards harmonized reporting of serum and urine protein electrophoresis
14. Multiple qualitative and quantitative methods for free light chain analysis are necessary as first line tests for AL amyloidosis
15. Use of isoelectric focusing to discriminate transient oligoclonal bands from monoclonal protein in treated myeloma
16. New patterns of relapse in multiple myeloma: a case of “light chain escape” in which FLC predicted relapse earlier than urine and serum immunofixation
17. Serum Free Light Chain Methods and Controversies
18. Analytical issues of serum free light chain assays and the relative performance of polyclonal and monoclonal based reagents
19. Measurement of free light chains with assays based on monoclonal antibodies
20. Measurement of free light chains – pros and cons of current methods
21. Is accuracy of serum free light chain measurement achievable?
22. Performance goals for immunoglobulins and serum free light chain measurements in plasma cell dyscrasias can be based on biological variation
23. A patient with AL amyloidosis with negative free light chain results
24. Strengths and weaknesses of methods for identifying monoclonal free light chains of Ig: examples from two cases with renal disease
25. Comparison of Freelite™ and N Latex serum free light chain assays in subjects with end stage kidney disease on haemodialysis
26. New Laboratory Assays and Challenges
27. Quantification of β-region IgA monoclonal proteins – should we include immunochemical Hevylite^® measurements? Point
28. Quantification of β region IgA paraproteins – should we include immunochemical “heavy/light chain” measurements? Counterpoint
29. Free light chains and heavy/light chains in monitoring POEMS patients
30. Monitoring free light chains in serum using mass spectrometry
31. Monoclonal antibody therapeutics as potential interferences on protein electrophoresis and immunofixation
32. Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference
33. Interference of daratumumab in monitoring multiple myeloma patients using serum immunofixation electrophoresis can be abrogated using the daratumumab IFE reflex assay (DIRA)
34. Letter to the Editor
35. Discrepancy between FLC assays: only a problem of quantification?